Key Takeaways CNMD will leave its gastroenterology lines, including an early end to its VIABIL stent distribution deal.CNMD shifts resources to minimally invasive and orthopedic soft tissue surgery for stronger margins.CNMD sees improved gross margin and flexibility ahead while reaffirming its 2025 revenue and EPS.CONMED (CNMD) recently announced its intention to exit its gastroenterology product lines, including an early conclusion of its distribution agreement with W. L. Gore & Associates, Inc. (Gore) for ...